| Literature DB >> 25203321 |
Xiaowen Hu1, Yi Feng2, Dongmei Zhang3, Sihai D Zhao4, Zhongyi Hu5, Joel Greshock2, Youyou Zhang5, Lu Yang6, Xiaomin Zhong7, Li-Ping Wang8, Stephanie Jean9, Chunsheng Li5, Qihong Huang10, Dionyssios Katsaros11, Kathleen T Montone8, Janos L Tanyi9, Yiling Lu12, Jeff Boyd13, Katherine L Nathanson14, Hongzhe Li15, Gordon B Mills12, Lin Zhang16.
Abstract
In a genome-wide survey on somatic copy-number alterations (SCNAs) of long noncoding RNA (lncRNA) in 2,394 tumor specimens from 12 cancer types, we found that about 21.8% of lncRNA genes were located in regions with focal SCNAs. By integrating bioinformatics analyses of lncRNA SCNAs and expression with functional screening assays, we identified an oncogene, focally amplified lncRNA on chromosome 1 (FAL1), whose copy number and expression are correlated with outcomes in ovarian cancer. FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a number of genes including CDKN1A. The oncogenic activity of FAL1 is partially attributable to its repression of p21. FAL1-specific siRNAs significantly inhibit tumor growth in vivo.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25203321 PMCID： PMC4159613 DOI： 10.1016/j.ccr.2014.07.009
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743